
Fennec Pharmaceuticals (FENC) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 12, 2026 | $0.12 | $0.10 | 20.0 % |
| Q2 | Aug 11, 2026 | $0.05 | $0.02 | 150.0 % |
| Q1 | May 14, 2026 | $0.01 | $-0.02 | 150.0 % |
| Q4 | Mar 24, 2026 | $-0.17 | $0.04 | -525.0 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 12, 2026 | $19.61M | $18.88M | 3.87 % |
| Q2 | Aug 11, 2026 | $17.87M | $16.09M | 11.1 % |
| Q1 | May 14, 2026 | $15.11M | $13.86M | 8.99 % |
| Q4 | Mar 24, 2026 | $13.78M | $14.83M | -7.09 % |
Fennec Pharmaceuticals (FENC) last issued guidance on February 29, 2024 for fiscal year 2023. The company guided revenue in the range of $20.7M - $21.2M for the period.
Compared to prior guidance, Fennec Pharmaceuticals raised its revenue forecast from a prior range of $9.2M - $9.7M.
Fennec Pharmaceuticals has issued 2 guidance updates between February 29, 2024 and February 29, 2024. During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.10 | $0.02 | $-0.02 | $0.04 |
| Actual | $0.12 | $0.05 | $0.01 | $-0.17 |
| Surprise | +20.0% | +150.0% | +150.0% | -525.0% |
| Revenue | ||||
| Estimate | $18.9M | $16.1M | $13.9M | $14.8M |
| Actual | $19.6M | $17.9M | $15.1M | $13.8M |
| Surprise | +3.87% | +11.1% | +8.99% | -7.09% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.18 | $0.15 | $0.21 | $0.27 |
| Revenue | ||||
| Consensus | $22.0M | $22.9M | — | — |